



SUVN-I6107

M1 True PAM - No Cholinergic Side Effects

(Muscarinic 1 True Positive Allosteric Modulator)

For Treatment of Cognitive Deficits



SUVN-I6107: Key Features



- Novel, potent and selective muscarinic M1 positive allosteric modulator (M1 PAM) with no agonist like activity
- Selective against muscarinic subtypes M2 to M5 (both orthosteric as well as allosteric site)
- Excellent ADME properties with no drug-drug interaction liability
- Good brain penetration and high CSF concentrations in rats
- Robust efficacy in preclinical animal models of cognition
- Potentiates the preclinical efficacy of current SOC for AD treatment (EEG)
- Dose dependent increase in the cortical sAPP α levels
- No Cholinergic effects like salivation, emesis or diarrhea in Beagle Dogs
- Excellent margin of safety in 7-day rat toxicity study
- Well protected intellectual property in all major markets

Current status: GLP toxicity studies in planning



Contacts:

Venkat Jasti

Chairman & CEO

E-mail: jasti@suven.com

Ramakrishna Nirogi

Vice President, Discovery Research

E-mail: nvsrk@suven.com